The study also found that the HeartMate 3 had an improved survival rate of 58%, compared to 44% with HeartMate II. Further, the device reduced morbidity and mortality compared to HeartMate II.

“The Heartmate 3 LVAS improved clinical outcomes in the MOMENTUM 3 study by avoiding the need for surgical reoperation to replace or remove the pump due to pump thrombosis,” said Dr. ...

ABBOTT PARK, Ill., Aug. 29, 2022/ PRNewswire/-- Abbott today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at ...

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data 1 have shown survival for ...

ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3 ™ Left ...

The HeartMate 3 consequently scored numerically better on the HCS, collecting only 101 points, compared to 137 points acquired by the smaller group on HeartMate II. Those in whom the HCS score was ...

The HeartMate 3 consequently scored numerically better on the HCS, collecting only 101 points, compared to 137 points acquired by the smaller group on HeartMate II. Those in whom the HCS score was ...

HeartMate 3: 'A Much More Forgiving Pump' — Final data from MOMENTUM 3 still shine for safety by Crystal Phend, Senior Associate Editor, MedPage Today March 18, 2019 • 3 min read ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events ...

The HeartMate 3 LVAS is not approved in the U.S. and limited by federal law to investigational use. About Left Ventricular Assist Devices Unlike artificial hearts, LVADs don’t replace the heart.

The HeartMate 3's predecessor, the HeartMate II, was priced similarly to the HeartWare. But design enhancements in the HeartMate 3 have led to lower rates of post-surgical complications.

The company announced plans last week to buy HeartMate's ­manufacturer, Thoratec Corp., in a $3.4 billion deal that would be St. Jude's biggest corporate acquisition ever.